Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    pipeline-prospector-insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Lonza Group

              • Deals

              Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

              SWITZERLAND Switzerland

              Contact Supplier Contact Supplier

              Virtual Booth Virtual Booth

              IFT Annual Expo

              Participation Not Confirmed

              Update your events

              Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus

              Contact the Supplier

              Lead Product(s): mRNA-1273

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Vaccine

              Partner/Sponsor/Collaborator: Moderna Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 01, 2020

              Details:

              Moderna plans to establish manufacturing suites at Lonza’s facilities in the United States and Switzerland for the manufacture of mRNA-1273 at both sites.

              DNDi

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              IFT Annual Expo

              Participation Not Confirmed

              Update your events

              Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis

              Contact the Supplier

              Lead Product(s): LXE408

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement February 25, 2020

              Details:

              Within the scope of the agreement, Novartis is responsible for completing Phase I clinical trials and DNDi will lead Phase II and Phase III development in India.

              PharmaCompass__DigitalAd